y90 dota anti-cea monoclonal antibody m5a
mAbexperimentalADC
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 9, 2006 (NCT00645060)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109373 ↗
Also known as
- m5a
- m5a
- m5a 90y
- y90 dota anti-cea monoclonal antibody m5a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05204147 | Phase 1 | Jun 2, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03993327 | Phase 1 | Aug 1, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01205022 | Phase 1 | Apr 1, 2011 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01320683 | Phase 2 | Mar 1, 2011 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00645060 | Phase 1 | Oct 9, 2006 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 5 | 5 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 5 | 0 | 2 | 2006 |
2 organizations
Page 1 / 1